Valneva SE (VALN) Income from Continuing Operations (2021 - 2026)
Valneva SE (VALN) posted quarterly Income from Continuing Operations of 34622258.7 for Q1 2026, down 384.17% year-on-year from 12183808.8 in Q1 2025, and up 39.25% on a QoQ basis from 56987611.95 in Q4 2025.
Valneva SE (VALN) Income from Continuing Operations (2021 - 2026) Analysis & Trends
Valneva SE (VALN) has reported Income from Continuing Operations for 6 consecutive years, with 34622258.7 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations fell 384.17% year-over-year to 34622258.7 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 158585307.23 (down 79.83% YoY) and the FY2025 annual result came in at 131113953.17, down 837.81% from the prior year.
- Income from Continuing Operations improved to 34622258.7 in Q1 2026 per VALN's latest filing, from 56987611.95 in the prior quarter.
- Over the last five years, Income from Continuing Operations for VALN reached as high as 82162574.29 in Q3 2022 and fell as low as 161491642.44 in Q2 2022.
- A 5-year average of 26951978.34 and a median of 28751552.62 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations surged 420.83% — and 2025, when it slumped 426.23%.
- Year by year, Income from Continuing Operations stood at 55224920.78 in 2022, then surged by 38.28% to 34084006.33 in 2023, then slipped by 23.69% to 42158929.84 in 2024, then sank by 35.17% to 56987611.95 in 2025, then soared by 39.25% to 34622258.7 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 34622258.7, 56987611.95, and 53283570.79 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Valneva SE | 803.90 Mn | 680.66 Mn | 5.38 Mn | -34.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.62 Mn |
| Dec 31, 2025 | -56.99 Mn |
| Sep 30, 2025 | -53.28 Mn |
| Jun 30, 2025 | -13.69 Mn |
| Mar 31, 2025 | -7.15 Mn |
| Dec 31, 2024 | -42.16 Mn |
| Sep 30, 2024 | -10.13 Mn |
| Jun 30, 2024 | -28.75 Mn |
| Mar 31, 2024 | 67.06 Mn |
| Dec 31, 2023 | -34.08 Mn |
| Sep 30, 2023 | -32.86 Mn |
| Jun 30, 2023 | -27.58 Mn |
| Mar 31, 2023 | -20.90 Mn |
| Dec 31, 2022 | -55.22 Mn |
| Sep 30, 2022 | 82.16 Mn |
| Jun 30, 2022 | -161.49 Mn |
| Mar 31, 2022 | -28.49 Mn |
| Dec 31, 2021 | 192.56 Mn |
| Sep 30, 2021 | -179.32 Mn |
| Jun 30, 2021 | -64.44 Mn |